Proapoptotic Protein Smac Mediates Apoptosis in Ovarian Cancer Cells When ‎Treated with the Carpachromene ‎

IntroductionWe also investigated the Carpachromene in the cytotoxicity studies against common human ovarian cancer cell ‎line i.e., SW 626, in-vitro.Material and methodsCell viability of Carpachromene was very low against common ‎human ovarian cancer ‎cell line i.e. SW 626 without any cytotoxicity on normal cell line. To compare the ‎biological activities of molecules, the enzymes used are α-glucosidase, acetylcholinesterase, respectively. Finally, ‎calculations were made using the molecular docking method to compare the biological activity of the ‎carpachromene molecule. We then examined whether the release of Smac is necessary for apoptosis in ovarian ‎cancer cells using the SW 626‎ cell line. We first examined mitochondrial and cytosolic Smac levels after ‎Carpachromene treatment. ‎ResultsFollowing the docking calculations, the properties of the carpachromene molecule ‎were examined by ADME/T analysis in order to be used as a drug in the future. In addition, the anti-oxidant ‎properties of the molecules were examined in both gas and water phase with the HF/6-31g basis set with the ‎Gaussian software program. As shown, exposure of ovarian cancer cells to Carpachromene decreased ‎mitochondrial Smac and increased cytosolic Smac levels in a time-dependent fashion. As depicted in results, a ‎decrease in Smac expression was confirmed by Western blot. Silencing of Smac significantly inhibited ‎Carpachromene-induced caspase-3 cleavage and attenuated apoptosis in these cells Moreover, overexpression of ‎a Smac heptapeptide (Smac-N7) enhanced Carpachromene-induced cell deathConclusionsAccording to the above findings, the Carpachromene may be administrated for the treatment of several types of ‎human ovarian cancer in humans. ‎

Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth

Ovarian cancer remains the leading cause of mortality among gynecological tumors. Estrogen receptor beta (ERβ) expression has been suggested to act as a tumor suppressor in epithelial ovarian cancer by reducing both tumor growth and metastasis. ERβ expression abnormalities represent a critical step in the development and progression of ovarian cancer: for these reasons, its re-expression by genetic engineering, as well as the use of targeted ERβ therapies, still constitute an important therapeutic approach. 3-{[2-chloro-1-(4-chlorobenzyl)-5-methoxy-6-methyl-1H-indol-3-yl]methylene}-5-hydroxy-6-methyl-1,3-dihydro-2H-indol-2-one, referred to here as compound 3, has been shown to have cytostatic as well cytotoxic effects on various hormone-dependent cancer cell lines. However, the mechanism of its anti-carcinogenic activity is not well understood. Here, we offer a possible explanation of such an effect in the human ovarian cancer cell line IGROV1. Chromatin binding protein assay and liquid chromatography mass spectrometry were exploited to localize and quantify compound 3 in cells. Molecular docking was used to prove compound 3 binding to ERβ. Mass spectrometry-based approaches were used to analyze histone post-translational modifications. Finally, gene expression analyses revealed a set of genes regulated by the ERβ/3 complex, namely CCND1, MYC, CDKN2A, and ESR2, providing possible molecular mechanisms that underline the observed antiproliferative effects.